October 11, 2006 -- Cephalon reported positive data from a Phase III trial of Fentora, a buccal table for breakthrough pain, Aspreva Pharma announced that CellCept was not effective for myasthenia gravis; Biovest said BiovaxID for follicular lymphoma was accepted into the European Rare Drug Registry; NitroMed axed 120 salespeople while it shifts its emphasis to the XR version of BiDil; Alnylam began a Phase I trial of a nebulized formulation of its RSV drug; and Medarex expects to receive $1 million to help develop its anthrax drug. The Centient Biotech 200™ close with a loss of 17 points at 3911, a drop of .45%. More details...
